-
US threatens 'devastating' response to any Iran attack on shipping
-
Murphy warns snooker hopefuls to 'work harder' to match Chinese stars
-
Race to find port for hantavirus-stricken cruise ship
-
Romanian pro-EU PM loses no-confidence motion
-
Stocks diverge as traders eye US-Iran ceasefire
-
Edin Terzic to become Athletic Bilbao coach next season
-
Borthwick backed by RFU to take England to 2027 Rugby World Cup
-
EU hails 'leap forward' in ties with Russia's ally Armenia
-
German car-ramming suspect had mental health problems: reports
-
Pyongyang calling: North Korea shows off own-brand phones
-
Iran warns 'not even started' in Hormuz
-
World body in dark over allegations against China badminton chief
-
Asian stocks drop amid fears over US-Iran ceasefire
-
China fireworks factory explosion kills 26, injures 61
-
China hails 'our era' as Wu Yize's world snooker triumph goes viral
-
Ex-model accuses French scout of grooming her for Epstein
-
Timberwolves eclipse Spurs as Knicks rout Sixers
-
Taiwan leader says island has 'right to engage with the world'
-
Yoko says oh no to 'John Lemon' beer
-
Bayern's Kompany promises repeat fireworks in PSG Champions League semi
-
A coaching great? Luis Enrique has PSG on brink of another Champions League final
-
Top five moments from the Met Gala
-
Brunson leads Knicks in rout of Sixers
-
Retiring great Sophie Devine wants New Zealand back playing Tests
-
Stocks sink amid fears over US-Iran ceasefire
-
G7 trade ministers set to meet but not discuss latest US tariff threat
-
Sherlock Holmes fans recreate fateful duel at Swiss falls
-
Premier League losses soar for clubs locked in 'arms race'
-
'Spreading like wildfire': Fiji grapples with soaring HIV cases
-
For Israel's Circassians, food and language sustain an ancient heritage
-
'Super El Nino' raises fears for Asia reeling from Middle East conflict
-
Trouble in paradise: Colombia tourist jewel plagued by violence
-
Death toll in Brazil small plane crash rises to three
-
Pulitzers honor damning coverage of Trump and his policies
-
Digi Power X Signs AI Colocation Agreement with Leading AI Compute Company for 40 MW Data Center in Columbiana, Alabama
-
LA fire suspect had grudge against wealthy: prosecutors
-
US-Iran ceasefire on brink as UAE reports attacks
-
Stars shine at Met Gala, fashion's biggest night
-
Birthday girl, 10, among dead in Colombia monster truck crash
-
Blake Lively, Justin Baldoni agree to end lengthy legal battle
-
Dolly Parton cancels Las Vegas shows over health concerns
-
Wu Yize: China's 'priest' who conquered the snooker world
-
China's Wu Yize wins World Snooker Championship for first time
-
Broadway theater blaze forces 'Book of Mormon' to close
-
Advantage Arsenal as Man City held in six-goal Everton thriller
-
Roma hammer Fiorentina to remain in Champions League hunt
-
MLB Tigers star pitcher Skubal to undergo elbow surgery
-
Oil prices jump on Hormuz tensions as US indices retreat from records
-
No.6 Morikawa withdraws from final PGA Championship tuneup
-
Ukraine and Russia declare separate truces
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
A.Ammann--VB